ANY1 Antibody

What is the AnnA1 antibody and what is its target?

The AnnA1 antibody is directed against truncated Annexin A1 protein. This antibody was originally developed as a mouse antibody (mAnnA1) that showed high tumor retention in pre-clinical cancer models. It was subsequently approved by the National Cancer Institute Experimental Therapeutics (NExT) program for humanization and large batch cGMP production for toxicology and clinical trials . The antibody targets the truncated version of Annexin A1 localized in caveolae of the endothelium, which has been shown to rapidly pump across tumor endothelium, achieving concentrations over 100-fold higher than other antibodies within one hour .

How does the structure of humanized AnnA1 (hAnnA1) differ from the mutated version (hAnnA1-mut)?

The hAnnA1-mut antibody resulted from an accidental single nucleotide deletion in the terminal Fc coding region during production by a contractor. This deletion caused a frameshift mutation in the heavy chain CH3 region that increased the translated size by eight amino acids (445 aa in hAnnA1 vs. 453 aa in hAnnA1-mut) and led to random alterations in the final twenty-four amino acids of the protein . The table below shows the key differences:

What purification methods are used for AnnA1 antibody production?

For hAnnA1 antibody purification, the process begins with harvesting antibodies by spinning out cell culture and filtering the supernatant (0.2 microns). The filtered supernatant is passed over a protein G column on AKTA fast protein liquid chromatography and washed with PBS (25 column volumes) until a stable baseline is achieved. Elution is performed with 0.1 M glycine, pH 2.6, and the peak is dialyzed against PBS before being sent for size exclusion chromatography (SEC) polishing. The final antibody is typically ~98% monomer . For the mutated version (hAnnA1-mut), production included an additional urea step for purification, while the correctly sequenced hAnnA1 was produced in CHO cells with transient expression and purified without the urea step .

What validation steps are critical for confirming AnnA1 antibody specificity?

Comprehensive validation for AnnA1 antibody should include DNA and amino acid sequencing to confirm the correct protein sequence. This is particularly important as demonstrated by the case of hAnnA1-mut, where a single nucleotide deletion at position 1423 caused a frameshift mutation leading to significant functional changes . Additional validation steps should include:

• ELISA against the purified recombinant protein (immunogen)

• ELISA against transfected heterologous cells expressing the antigen of interest

• Immunohistochemistry on relevant tissues

• Western blot analysis to confirm target specificity

• Biodistribution studies to assess tissue uptake patterns

These validation steps align with recommendations from antibody characterization initiatives that stress the importance of testing antibodies in multiple assays beyond simple ELISA, as ELISA positivity alone may not predict utility in other common research applications .

How can researchers differentiate between properly humanized AnnA1 and potentially modified versions?

Researchers should employ a multi-step verification process:

• Conduct DNA sequencing of the antibody coding sequence, with special attention to the Fc region where mutations like the one in hAnnA1-mut can occur .

• Perform non-reducing gel electrophoresis to detect potential binding of serum proteins, as demonstrated with IR680-labeled antibodies incubated with mouse sera, which showed an upward shift in hAnnA1-mut consistent with serum protein binding .

• Evaluate biodistribution patterns in animal models using radiolabeled antibodies, comparing results with standard IgG controls. Significantly higher liver and spleen uptake may indicate modifications that alter normal antibody circulation .

• Consider size exclusion chromatography to verify the monomeric state of the antibody, as properly processed hAnnA1 should be approximately 98% monomer .

How do modifications in the Fc region of AnnA1 antibody affect its biodistribution?

Modifications in the Fc region significantly impact biodistribution patterns, particularly regarding reticuloendothelial system (RES) uptake. Research has shown that the hAnnA1-mut, with its altered Fc terminal region, demonstrates significantly higher uptake in the liver and spleen compared to properly humanized hAnnA1 . This uptake pattern suggests recognition by the innate immune system, likely through complement protein binding, leading to accelerated clearance from circulation. Quantitative biodistribution studies have shown that properly humanized hAnnA1 has low spleen and liver retention, not statistically different from standard human IgG1 and mouse AnnA1 controls, with correspondingly higher blood levels. In contrast, hAnnA1-mut shows significantly elevated levels in spleen and liver tissues .

What factors influence the level of liver and spleen uptake of modified AnnA1 antibodies?

Several factors have been shown to influence RES uptake of modified antibodies:

• Mouse strain: Differences in uptake have been identified among various mouse strains including C57BL/6, FVB, and BALB/c nude mice, with the highest splenic uptake observed in BALB/c nude mice .

• Conjugation ratio: Increasing the molar conjugation ratio (HYNIC:Ab) from 1:1 to 6:1 increases RES uptake of Tc-99m-HYNIC-hAnnA1-mut for both C57BL/6 and FVB mice. Higher conjugation ratios mean more structural changes to the antibody, making it more likely to be recognized as foreign .

• Administration route: Different injection routes (IV vs. IP) can affect biodistribution patterns, though the specific differences for AnnA1 antibodies depend on other factors like mouse strain and conjugation ratio .

• Structural modifications: Even minor modifications can significantly increase RES uptake for antibodies with altered constant region structures (like hAnnA1-mut) while having minimal impact on antibodies with intact constant regions .

What radiolabeling methods are optimal for AnnA1 antibody biodistribution studies?

For biodistribution studies of AnnA1 antibodies, Tc-99m-HYNIC (hydrazinonicotinamide) radiolabeling has been effectively used. The process typically involves:

• Conjugation of HYNIC to the antibody at varying molar ratios (1:1 or 6:1)

• Purification of the conjugate

• Radiolabeling with Tc-99m to achieve a final purity > 98%

Alternative methods include Zr-89-DFO (desferrioxamine) labeling, which has been used for PET/CT imaging of AnnA1 antibody distribution 7 days post-injection . The choice of radiolabeling method should consider the intended imaging modality, required half-life for the study duration, and potential impact of the chelator on antibody biodistribution. For AnnA1 specifically, researchers should be aware that higher chelator:antibody molar conjugation ratios may increase RES uptake, particularly for modified versions like hAnnA1-mut .

How can trans-vascular pumping of AnnA1 antibody be optimized for tumor targeting?

Optimizing trans-vascular pumping of AnnA1 antibody for tumor targeting requires:

• Maintaining antibody structural integrity: Ensure the correct protein sequence with proper handling to prevent unwanted modifications that can lead to RES uptake and reduced blood levels .

• Verifying target expression: Confirm expression of both truncated Annexin A1 and caveolin 1 in the tumor vasculature, as the trans-vascular pumping mechanism requires both proteins .

• Optimizing conjugation strategy: When conjugating therapeutic or diagnostic payloads to AnnA1, minimize the conjugation ratio to prevent structural changes that might impair the antibody's ability to engage in trans-vascular pumping .

• Considering tumor type: The pumping mechanism appears particularly relevant for cancers characterized by scattered metastases, such as ovarian cancer, where active transport through vascular endothelium can enhance targeting of disseminated tumors .

How does the complement system interact with modified AnnA1 antibodies?

The interaction between the complement system and modified AnnA1 antibodies, particularly hAnnA1-mut, appears to be a key factor in their altered biodistribution. Gel electrophoresis studies showed an upward shift of hAnnA1-mut consistent with the binding of blood serum protein, likely complement proteins . This binding appears to trigger recognition by the reticuloendothelial system (RES), leading to increased uptake in liver and spleen. The random 24 amino acids at the Fc end of hAnnA1-mut likely create structural epitopes that are recognized by the innate immune system, particularly complement proteins . Researchers investigating complement interactions should consider:

• Using non-reducing gel electrophoresis with labeled antibodies incubated with serum to detect complement binding

• Comparing biodistribution in complement-deficient versus normal mouse models

• Analyzing the specific complement components that may be binding to the modified regions

What are the implications of AnnA1 antibody research for developing targeted cancer therapies?

AnnA1 antibody research has significant implications for developing targeted cancer therapies:

• Enhanced tumor delivery: The ability of AnnA1 to be actively pumped into tumors through vascular endothelium can potentially enhance targeting of disseminated cancers unsuitable for surgery, such as ovarian cancer with peritoneal metastases .

• Radioimmunotherapy potential: Conjugating AnnA1 antibody with radioisotopes may add enhanced tumor-killing potential by eliciting direct DNA damage leading to cell death, making it a promising therapeutic approach .

• Reduced off-target effects: Properly humanized AnnA1 (hAnnA1) shows low liver and spleen uptake comparable to standard IgG1, suggesting minimal off-target effects when the antibody structure is correctly maintained .

• Design considerations: The research emphasizes the importance of avoiding modifications to antibodies, particularly in the Fc region, to prevent uptake in non-target organs and maintain optimal blood levels for tumor targeting .

How can researchers identify and address problems with antibody sequence integrity?

Researchers can identify and address antibody sequence integrity problems through:

• Regular DNA sequencing verification: Implement DNA sequencing as part of routine quality control, especially focusing on regions prone to mutations like the terminal Fc coding region where the single nucleotide deletion occurred in hAnnA1-mut .

• Protein analysis: Conduct SDS-PAGE and mass spectrometry to verify the correct molecular weight and detect any unexpected size variations that might indicate sequence alterations .

• Functional testing: Compare suspected altered antibodies with known standards using functional assays relevant to the intended application, such as binding assays, cellular uptake studies, or biodistribution analysis .

• Production protocol review: When unexpected results occur, review the production protocol for steps that might introduce mutations or modifications, such as the use of urea in purification which was part of the process for hAnnA1-mut but not for correctly sequenced hAnnA1 .

What quality control measures should be implemented for large-scale AnnA1 antibody production?

For large-scale AnnA1 antibody production, the following quality control measures should be implemented:

• Master cell bank verification: Conduct rigorous analysis of the master cell bank to confirm the transgene sequence, as was done for the hAnnA1 production where sequence testing identified the mutation in hAnnA1-mut .

• Regular sequence testing: Implement regular DNA and amino acid sequencing throughout the production process to catch any mutations early.

• Functional comparisons: Perform biodistribution studies comparing newly produced batches with established standards to ensure consistent performance .

• Purification process standardization: Standardize purification protocols, avoiding modifications that might alter antibody structure or function, as differences in processes (such as the urea step used for hAnnA1-mut) may impact the final product .

• Batch-to-batch consistency testing: Implement rigorous testing between batches to ensure consistent antibody performance, particularly for parameters known to be sensitive to production variations .